成都欧林生物科技股份有限公司2025年年度业绩快报公告

Financial Data Summary - The company reported preliminary financial data for the year 2025, with total revenue of 704.16 million RMB, representing a year-on-year increase of 19.58% [1] - The net profit attributable to the parent company was 22.23 million RMB, showing a year-on-year growth of 7.10% [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was 9.88 million RMB, which reflects a year-on-year decrease of 11.64% [1] Operational Performance - The company has strengthened market promotion efforts, leading to steady growth in the sales of tetanus vaccines [1] - Total assets at the end of the reporting period amounted to 2,019.99 million RMB, an increase of 11.78% compared to the beginning of the period [2] - The equity attributable to the parent company was 903.68 million RMB, which decreased by 2.27% from the beginning of the period [2] Profitability Metrics - Operating profit increased by 44.80% year-on-year, primarily due to the growth in operating revenue [2] - Total profit rose by 43% year-on-year, also driven by the increase in operating revenue [3]